HLSE:ORNBV - アナリストの将来予測と過去の財務データ ( )EUR Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	1,619	323	217	325	4
12/31/2025	1,453	248	201	276	6
12/31/2024	1,377	243	177	294	6
3/31/2024	1,220	217	140	225	N/A
12/31/2023	1,190	217	2	119	N/A
9/30/2023	1,163	173	-45	76	N/A
6/30/2023	1,354	306	277	389	N/A
3/31/2023	1,348	336	293	405	N/A
12/31/2022	1,341	350	361	434	N/A
9/30/2022	1,323	351	444	505	N/A
6/30/2022	1,072	202	111	199	N/A
3/31/2022	1,043	192	122	205	N/A
12/31/2021	1,041	194	131	216	N/A
9/30/2021	1,020	187	115	195	N/A
6/30/2021	1,029	192	203	252	N/A
3/31/2021	1,067	212	238	284	N/A
12/31/2020	1,078	220	258	299	N/A
9/30/2020	1,097	240	269	308	N/A
6/30/2020	1,131	260	280	320	N/A
3/31/2020	1,090	225	226	267	N/A
12/31/2019	1,051	200	235	271	N/A
9/30/2019	1,039	209	208	270	N/A
6/30/2019	977	172	163	224	N/A
3/31/2019	971	187	166	227	N/A
12/31/2018	978	197	164	231	N/A
9/30/2018	981	198	166	214	N/A
6/30/2018	1,001	206	178	241	N/A
3/31/2018	1,015	206	160	234	N/A
12/31/2017	1,034	219	N/A	228	N/A
9/30/2017	1,048	212	N/A	249	N/A
6/30/2017	1,065	242	N/A	241	N/A
3/31/2017	1,077	253	N/A	259	N/A
12/31/2016	1,074	249	N/A	249	N/A
9/30/2016	1,055	241	N/A	248	N/A
6/30/2016	1,036	214	N/A	240	N/A
3/31/2016	1,018	206	N/A	245	N/A
12/31/2015	1,016	208	N/A	255	N/A
9/30/2015	1,009	210	N/A	252	N/A
6/30/2015	1,009	214	N/A	251	N/A
3/31/2015	1,030	224	N/A	301	N/A
12/31/2014	1,015	211	N/A	297	N/A
9/30/2014	1,033	226	N/A	317	N/A
6/30/2014	1,031	226	N/A	306	N/A
3/31/2014	1,003	203	N/A	246	N/A
12/31/2013	1,007	206	N/A	215	N/A
9/30/2013	989	193	N/A	185	N/A
6/30/2013	998	201	N/A	198	N/A

アナリストによる今後の成長予測

収入対貯蓄率: ORNBVの予測収益成長率 (年間11.1% ) は貯蓄率 ( 1% ) を上回っています。

収益対市場: ORNBVの収益 ( 11.1% ) Finnish市場 ( 14.8% ) よりも低い成長が予測されています。

高成長収益: ORNBVの収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: ORNBVの収益 ( 7.7% ) Finnish市場 ( 3.1% ) よりも速いペースで成長すると予測されています。

高い収益成長: ORNBVの収益 ( 7.7% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ORNBVの自己資本利益率は、3年後には高くなると予測されています ( 28.7 %)

Orion Oyj 将来の成長

Future 基準チェック /36

主要情報

今後の成長に関する最新情報

Orion Oyj Just Missed EPS By 5.4%: Here's What Analysts Think Will Happen Next

Price target decreased by 9.2% to €39.90

Earnings Beat: Orion Oyj Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Price target decreased by 8.5% to €41.39

Orion Oyj Provides Earnings Guidance for the Year 2023

Orion Group Provides Earnings Guidance for the Full Year 2022

Recent updates

Orion Oyj's (HEL:ORNBV) Shares May Have Run Too Fast Too Soon

Here's Why Orion Oyj (HEL:ORNBV) Can Manage Its Debt Responsibly

Orion Corporation Announces Change in Orion Group Executive Management Board as of 31 May 2025

We Think That There Are More Issues For Orion Oyj (HEL:ORNBV) Than Just Sluggish Earnings

Orion Oyj Just Missed EPS By 5.4%: Here's What Analysts Think Will Happen Next

Orion Corporation Announces Appointments to Nomination Committee

First quarter 2024 earnings released

Orion Corporation Announces Change in Executive Management Board, Effect as of 1 April 2024

Orion Corporation Approves Board Appointments

Upcoming dividend of €0.81 per share

Full year 2023 earnings: EPS exceeds analyst expectations

Price target decreased by 9.2% to €39.90

Earnings Beat: Orion Oyj Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Full year 2023 earnings: EPS exceeds analyst expectations

Orion Oyj Announces Retirement of Mikael Silvennoinen as Board Member

Why Investors Shouldn't Be Surprised By Orion Oyj's (HEL:ORNBV) P/E

Orion Oyj Announces CFO Changes

Orion Oyj (HEL:ORNBV) Has A Pretty Healthy Balance Sheet

Are Investors Undervaluing Orion Oyj (HEL:ORNBV) By 43%?

Orion Corporation Announces Phase 3 Clinical Trials with ODM-208 (MK-5684) posted to ClinicalTrials.gov Database

Orion Corporation Receives Fda Approval for Bonqat (Pregabalin Oral Solution)

We Think That There Are More Issues For Orion Oyj (HEL:ORNBV) Than Just Sluggish Earnings

New major risk - Earnings quality

Third quarter 2023 earnings: Revenues exceed analyst expectations

Orion Oyj (HEL:ORNBV) Could Easily Take On More Debt

Orion Group Appoints Julia Macharey as Senior Vice President, People & Cultur

Orion Oyj's (HEL:ORNBV) Intrinsic Value Is Potentially 51% Above Its Share Price

Now 20% undervalued after recent price drop

Orion Oyj to Report Q3, 2024 Results on Oct 29, 2024

Second quarter 2023 earnings: Revenues miss analyst expectations

Orion Oyj Announces Resignation of Jari Karlson as Chief Financial Officer

Now 21% undervalued after recent price drop

Is Orion Oyj (HEL:ORNBV) Using Too Much Debt?

Independent Chairman recently sold €76k worth of stock

A Look At The Intrinsic Value Of Orion Oyj (HEL:ORNBV)

First quarter 2023 earnings: Revenues miss analyst expectations

Here's Why We Think Orion Oyj (HEL:ORNBV) Is Well Worth Watching

Orion Oyj (HEL:ORNBV) Could Easily Take On More Debt

Upcoming dividend of €1.60 per share at 3.7% yield

Insider recently sold €233k worth of stock

Price target decreased by 8.5% to €41.39

Orion Oyj's (HEL:ORNBV) Upcoming Dividend Will Be Larger Than Last Year's

Full year 2022 earnings: EPS misses analyst expectations

Orion Oyj Provides Earnings Guidance for the Year 2023

A Look At The Intrinsic Value Of Orion Oyj (HEL:ORNBV)

Orion Oyj Announces Positive CHMP Opinion for Darolutamide in Combination with Docetaxel for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer

Orion Group Provides Earnings Guidance for the Full Year 2022

Orion Group Appoints Liisa Hurme as CEO, Effective 1 January 2023

Is Orion Oyj (HEL:ORNBV) Trading At A 29% Discount?

Orion Oyj (HEL:ORNBV) Seems To Use Debt Quite Sensibly

Orion Oyj Announces Executive Changes

Consensus forecasts updated

Orion Announces Approval of Additional Indication of Darolutamide in Combination with Docetaxel for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer (Mhspc) from U.S. FDA

Consensus revenue estimates increase by 13%

This Just In: Analysts Are Boosting Their Orion Oyj (HEL:ORNBV) Outlook for This Year

Second quarter 2022 earnings: Revenues exceed analyst expectations

Orion Oyj to Report Nine Months, 2023 Results on Oct 26, 2023

Orion Oyj to Report Q1, 2023 Results on Apr 27, 2023

Orion Oyj Revises Earnings Guidance for the Full Year 2022

Is There An Opportunity With Orion Oyj's (HEL:ORNBV) 34% Undervaluation?

Orion Oyj to Report Q2, 2022 Results on Jul 15, 2022

Orion Oyj (HLSE : ORNBV) acquired V.M.D. n.v./s.a. from Inovet Bv for €130 million.

Orion Oyj (HLSE : ORNBV) acquired V.M.D. n.v./s.a.from Inovet Bv for €130 million.

Does Orion Oyj (HEL:ORNBV) Have A Healthy Balance Sheet?

Orion Oyj Announces Executive Changes

First quarter 2022 earnings: Revenues in line with analyst expectations

Price target increased to €39.62

Orion Oyj Appoints Liisa Hurme as President and the Chair of the Executive Management Board, as of 1 November 2022

Are Investors Undervaluing Orion Oyj (HEL:ORNBV) By 34%?